Where Is the Data? Delayed and Chronic irAE Surveillance and Management After Cessation of ICIs: Expert Insights From SITC on Survivorship Care and the Need for Long-Term Data

    March 2026 in “ Journal for ImmunoTherapy of Cancer ”
    Tessa Flores, Emily S. Tonorezos, Shailender Bhatia, Julie R. Brahmer, Laura C. Cappelli, Monica T. Cooper, Marianne Davies, Samantha Guild, Krishna S. Gunturu, John B A G Haanen, D. Johnson, Mario E. Lacouture, Rom S. Leidner, Sandra Mitchell, F. Perry Wilson, Javid J. Moslehi, Jarushka Naidoo, M. Obeid, Michael A. Postow, Igor Puzanov, Mary E. Reid, Bianca Santomasso, Dirk Schadendorf, Ann W. Silk, Ryan J Sullivan, Thomas Bolig, Xingru Li, Paolo A Ascierto, Marc S Ernstoff
    Studysummary This paper reports insights from an Expert Panel convened by the Society for Immunotherapy of Cancer on managing immune-related adverse events (irAEs) following immune checkpoint inhibitor therapy, highlighting surveillance gaps and the need for a comprehensive irAE registry to improve post-treatment care for cancer survivors.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →